Powering complex CNS studies
Learn about uMotif’s experience in advancing CNS research, from our origin in supporting Parkinson’s patients to clinical trials in Major Depressive Disorder, Alzheimer’s, Schizophrenia and other chronic conditions.
By designing data capture technology to meet the needs of all stakeholders, uMotif’s eCOA platform makes a measurable impact on clinical trials and real-world studies.
Webinar: Enrolling patients, maintaining engagement, and tracking cognition in clinical trials
Listen to our expert panel delve into the evolving challenges and strategies in trials involving cognition—particularly those related to Alzheimer’s Disease—and how clinicians can better support the recruitment process.
Explore uMotif’s eCOA capabilities
CNS research is complicated—requiring the capture of many types and formats of data from a diverse set of stakeholders. uMotif’s modern eCOA capabilities are designed to drive the engagement and effective data capture that today’s CNS researchers require for successful and efficient studies.
Recent work in Psychedelics
Explore how uMotif is supporting complex trials that seek to identify and understand the impact of psychedelics on CNS conditions.
Patient perspective
Listen to Cathy describe her experience using the uMotif app as part of the large-scale 100 for Parkinson’s research study. Read the full story to learn more about how patients used the uMotif app to track symptoms during the study and long after it concluded.
CNS industry partnerships
Read how uMotif and Cogstate continue to build on existing work together—bringing sponsors and CROs the combined power of uMotif’s modern, patient-centric eCOA/ePRO platform and Cogstate’s market-leading, cognitive testing services for digital assessments and rater training and monitoring.
Learn more about how our partnership with MoCA Cognition brings uMotif’s robust eCOA/ePRO, the MoCA Test and the New XpressO mobile app to clinical trials and real-world studies. MoCA Cognition, whose MoCA Test was ranked No. 1 among 53 cognitive screening tests in a 2023 global Delphi Consensus.